The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Oncology Biosimilars-Global Market Insights and Sales Trends 2025
Synopsis
Biosimilar is the identical copy of oncology biologics used for the treatment of cancer and officially approved for the treatment of cancer. These molecules are cost-effective, efficient, and have the same ability as biologics. These molecules are easy to manufacture as compared to biologics and can only be manufactured after patent expiry. Earlier there were various patented biologics available in the market but nowadays most of the patents have expired and few are on the verge of patent expiry. In the past few years, various biosimilars have been approved by FDA for the treatment of various types of cancer such as blood cancer, colorectal cancer, breast cancer, and others. In the near future, it is expected that a few more biosimilars will be introduced in the market thus supporting the growth of the market.
The global Oncology Biosimilars market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Oncology Biosimilars in various end use industries. The expanding demands from the Retail Pharmacies, Hospital Pharmacy and Online Pharmacy,, are propelling Oncology Biosimilars market. Monoclonal Antibody, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Hematopoietic Agents segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Oncology Biosimilars, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Oncology Biosimilars market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Oncology Biosimilars market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Oncology Biosimilars sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Oncology Biosimilars covered in this report include Celltrion, Biocon, Dr. Reddy’s Laboratories, STADA Arzneimittel AG, Intas Pharmaceuticals, Pfizer, Sandoz International, Teva Pharmaceutical Industries Ltd and Apotex, etc.
The global Oncology Biosimilars market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Celltrion
Biocon
Dr. Reddy’s Laboratories
STADA Arzneimittel AG
Intas Pharmaceuticals
Pfizer
Sandoz International
Teva Pharmaceutical Industries Ltd
Apotex
BIOCAD
Global Oncology Biosimilars market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Oncology Biosimilars market, Segment by Type:
Monoclonal Antibody
Hematopoietic Agents
G-CSF
Others
Global Oncology Biosimilars market, by Application
Retail Pharmacies
Hospital Pharmacy
Online Pharmacy
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Oncology Biosimilars companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Biosimilar is the identical copy of oncology biologics used for the treatment of cancer and officially approved for the treatment of cancer. These molecules are cost-effective, efficient, and have the same ability as biologics. These molecules are easy to manufacture as compared to biologics and can only be manufactured after patent expiry. Earlier there were various patented biologics available in the market but nowadays most of the patents have expired and few are on the verge of patent expiry. In the past few years, various biosimilars have been approved by FDA for the treatment of various types of cancer such as blood cancer, colorectal cancer, breast cancer, and others. In the near future, it is expected that a few more biosimilars will be introduced in the market thus supporting the growth of the market.
The global Oncology Biosimilars market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Oncology Biosimilars in various end use industries. The expanding demands from the Retail Pharmacies, Hospital Pharmacy and Online Pharmacy,, are propelling Oncology Biosimilars market. Monoclonal Antibody, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Hematopoietic Agents segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Oncology Biosimilars, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Oncology Biosimilars market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Oncology Biosimilars market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Oncology Biosimilars sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Oncology Biosimilars covered in this report include Celltrion, Biocon, Dr. Reddy’s Laboratories, STADA Arzneimittel AG, Intas Pharmaceuticals, Pfizer, Sandoz International, Teva Pharmaceutical Industries Ltd and Apotex, etc.
The global Oncology Biosimilars market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Celltrion
Biocon
Dr. Reddy’s Laboratories
STADA Arzneimittel AG
Intas Pharmaceuticals
Pfizer
Sandoz International
Teva Pharmaceutical Industries Ltd
Apotex
BIOCAD
Global Oncology Biosimilars market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Oncology Biosimilars market, Segment by Type:
Monoclonal Antibody
Hematopoietic Agents
G-CSF
Others
Global Oncology Biosimilars market, by Application
Retail Pharmacies
Hospital Pharmacy
Online Pharmacy
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Oncology Biosimilars companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Oncology Biosimilars
1.1 Oncology Biosimilars Market Overview
1.1.1 Oncology Biosimilars Product Scope
1.1.2 Oncology Biosimilars Market Status and Outlook
1.2 Global Oncology Biosimilars Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Oncology Biosimilars Market Size by Region (2018-2029)
1.4 Global Oncology Biosimilars Historic Market Size by Region (2018-2023)
1.5 Global Oncology Biosimilars Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Oncology Biosimilars Market Size (2018-2029)
1.6.1 North America Oncology Biosimilars Market Size (2018-2029)
1.6.2 Europe Oncology Biosimilars Market Size (2018-2029)
1.6.3 Asia-Pacific Oncology Biosimilars Market Size (2018-2029)
1.6.4 Latin America Oncology Biosimilars Market Size (2018-2029)
1.6.5 Middle East & Africa Oncology Biosimilars Market Size (2018-2029)
2 Oncology Biosimilars Market by Type
2.1 Introduction
2.1.1 Monoclonal Antibody
2.1.2 Hematopoietic Agents
2.1.3 G-CSF
2.1.4 Others
2.2 Global Oncology Biosimilars Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Oncology Biosimilars Historic Market Size by Type (2018-2023)
2.2.2 Global Oncology Biosimilars Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Oncology Biosimilars Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Oncology Biosimilars Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Oncology Biosimilars Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Oncology Biosimilars Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Oncology Biosimilars Revenue Breakdown by Type (2018-2029)
3 Oncology Biosimilars Market Overview by Application
3.1 Introduction
3.1.1 Retail Pharmacies
3.1.2 Hospital Pharmacy
3.1.3 Online Pharmacy
3.2 Global Oncology Biosimilars Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Oncology Biosimilars Historic Market Size by Application (2018-2023)
3.2.2 Global Oncology Biosimilars Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Oncology Biosimilars Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Oncology Biosimilars Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Oncology Biosimilars Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Oncology Biosimilars Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Oncology Biosimilars Revenue Breakdown by Application (2018-2029)
4 Oncology Biosimilars Competition Analysis by Players
4.1 Global Oncology Biosimilars Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Oncology Biosimilars as of 2022)
4.3 Date of Key Players Enter into Oncology Biosimilars Market
4.4 Global Top Players Oncology Biosimilars Headquarters and Area Served
4.5 Key Players Oncology Biosimilars Product Solution and Service
4.6 Competitive Status
4.6.1 Oncology Biosimilars Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Celltrion
5.1.1 Celltrion Profile
5.1.2 Celltrion Main Business
5.1.3 Celltrion Oncology Biosimilars Products, Services and Solutions
5.1.4 Celltrion Oncology Biosimilars Revenue (US$ Million) & (2018-2023)
5.1.5 Celltrion Recent Developments
5.2 Biocon
5.2.1 Biocon Profile
5.2.2 Biocon Main Business
5.2.3 Biocon Oncology Biosimilars Products, Services and Solutions
5.2.4 Biocon Oncology Biosimilars Revenue (US$ Million) & (2018-2023)
5.2.5 Biocon Recent Developments
5.3 Dr. Reddy’s Laboratories
5.3.1 Dr. Reddy’s Laboratories Profile
5.3.2 Dr. Reddy’s Laboratories Main Business
5.3.3 Dr. Reddy’s Laboratories Oncology Biosimilars Products, Services and Solutions
5.3.4 Dr. Reddy’s Laboratories Oncology Biosimilars Revenue (US$ Million) & (2018-2023)
5.3.5 STADA Arzneimittel AG Recent Developments
5.4 STADA Arzneimittel AG
5.4.1 STADA Arzneimittel AG Profile
5.4.2 STADA Arzneimittel AG Main Business
5.4.3 STADA Arzneimittel AG Oncology Biosimilars Products, Services and Solutions
5.4.4 STADA Arzneimittel AG Oncology Biosimilars Revenue (US$ Million) & (2018-2023)
5.4.5 STADA Arzneimittel AG Recent Developments
5.5 Intas Pharmaceuticals
5.5.1 Intas Pharmaceuticals Profile
5.5.2 Intas Pharmaceuticals Main Business
5.5.3 Intas Pharmaceuticals Oncology Biosimilars Products, Services and Solutions
5.5.4 Intas Pharmaceuticals Oncology Biosimilars Revenue (US$ Million) & (2018-2023)
5.5.5 Intas Pharmaceuticals Recent Developments
5.6 Pfizer
5.6.1 Pfizer Profile
5.6.2 Pfizer Main Business
5.6.3 Pfizer Oncology Biosimilars Products, Services and Solutions
5.6.4 Pfizer Oncology Biosimilars Revenue (US$ Million) & (2018-2023)
5.6.5 Pfizer Recent Developments
5.7 Sandoz International
5.7.1 Sandoz International Profile
5.7.2 Sandoz International Main Business
5.7.3 Sandoz International Oncology Biosimilars Products, Services and Solutions
5.7.4 Sandoz International Oncology Biosimilars Revenue (US$ Million) & (2018-2023)
5.7.5 Sandoz International Recent Developments
5.8 Teva Pharmaceutical Industries Ltd
5.8.1 Teva Pharmaceutical Industries Ltd Profile
5.8.2 Teva Pharmaceutical Industries Ltd Main Business
5.8.3 Teva Pharmaceutical Industries Ltd Oncology Biosimilars Products, Services and Solutions
5.8.4 Teva Pharmaceutical Industries Ltd Oncology Biosimilars Revenue (US$ Million) & (2018-2023)
5.8.5 Teva Pharmaceutical Industries Ltd Recent Developments
5.9 Apotex
5.9.1 Apotex Profile
5.9.2 Apotex Main Business
5.9.3 Apotex Oncology Biosimilars Products, Services and Solutions
5.9.4 Apotex Oncology Biosimilars Revenue (US$ Million) & (2018-2023)
5.9.5 Apotex Recent Developments
5.10 BIOCAD
5.10.1 BIOCAD Profile
5.10.2 BIOCAD Main Business
5.10.3 BIOCAD Oncology Biosimilars Products, Services and Solutions
5.10.4 BIOCAD Oncology Biosimilars Revenue (US$ Million) & (2018-2023)
5.10.5 BIOCAD Recent Developments
6 North America
6.1 North America Oncology Biosimilars Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Oncology Biosimilars Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Oncology Biosimilars Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Oncology Biosimilars Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Oncology Biosimilars Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Oncology Biosimilars Market Dynamics
11.1 Oncology Biosimilars Industry Trends
11.2 Oncology Biosimilars Market Drivers
11.3 Oncology Biosimilars Market Challenges
11.4 Oncology Biosimilars Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
